Model Examples

If there’s a common thread running through our CEO interview coverage in Pharmaceutical Executive’s May issue, it might be this: The next phase of biopharma leadership will likely be defined by how boldly life sciences companies rethink the systems behind innovation.

In our cover profile, John Oyler’s journey with BeOne Medicines is a case study in just that. What began as a challenge to the cost and complexity of drug development has evolved into a full-scale reengineering of the model itself — bringing clinical operations, manufacturing and data capabilities in-house to drive speed, scale and access. The intention is not only “doing better science”; it’s also ensuring that innovation actually reaches patients, globally and efficiently. That mindset of questioning long-held assumptions and building with purpose is what’s propelled BeOne from startup to a profitable, global oncology player.

On a different front, Angela Schwab, CEO of Trialynx, zeroes in on another system overdue for reinvention: clinical trial design. Her message in our Q&A is equally clear. The traditional, manual approach — copy, paste, repeat — has baked inefficiencies and high failure rates into the process. AI, when applied thoughtfully, offers a way forward, not as a shortcut, but as a decision engine, Schwab notes, that can predict risks, streamline protocols and reduce unnecessary burden on patients and sites.

Both these perspectives point to a broader shift that we’ve discussed here before. Innovation is no longer just about new molecules. It’s about redesigning the pathways that bring them to life.

Thanks for reading.

Mike Hennessy Jr. is Chairman and CEO of MJH Life Sciences^®